Open Access

Skeletal muscle oxygen saturation does not estimate mixed venous oxygen saturation in patients with severe left heart failure and additional severe sepsis or septic shock

Critical Care200711:R6

https://doi.org/10.1186/cc5153

Received: 13 October 2006

Accepted: 16 January 2007

Published: 16 January 2007

Abstract

Introduction

Low cardiac output states such as left heart failure are characterized by preserved oxygen extraction ratio, which is in contrast to severe sepsis. Near infrared spectroscopy (NIRS) allows noninvasive estimation of skeletal muscle tissue oxygenation (StO2). The aim of the study was to determine the relationship between StO2 and mixed venous oxygen saturation (SvO2) in patients with severe left heart failure with or without additional severe sepsis or septic shock.

Methods

Sixty-five patients with severe left heart failure due to primary heart disease were divided into two groups: groups A (n = 24) and B (n = 41) included patients without and with additional severe sepsis/septic shock, respectively. Thenar muscle StO2 was measured using NIRS in the patients and in 15 healthy volunteers.

Results

StO2 was lower in group A than in group B and in healthy volunteers (58 ± 13%, 90 ± 7% and 84 ± 4%, respectively; P < 0.001). StO2 was higher in group B than in healthy volunteers (P = 0.02). In group A StO2 correlated with SvO2 (r = 0.689, P = 0.002), although StO2 overestimated SvO2 (bias -2.3%, precision 4.6%). In group A changes in StO2 correlated with changes in SvO2 (r = 0.836, P < 0.001; ΔSvO2 = 0.84 × ΔStO2 - 0.67). In group B important differences between these variables were observed. Plasma lactate concentrations correlated negatively with StO2 values only in group A (r = -0.522, P = 0.009; lactate = -0.104 × StO2 + 10.25).

Conclusion

Skeletal muscle StO2 does not estimate SvO2 in patients with severe left heart failure and additional severe sepsis or septic shock. However, in patients with severe left heart failure without additional severe sepsis or septic shock, StO2 values could be used to provide rapid, noninvasive estimation of SvO2; furthermore, the trend in StO2 may be considered a surrogate for the trend in SvO2.

Trial Registration: NCT00384644

Introduction

Maintenance of adequate oxygen delivery (DO2) is essential to preservation of organ function, because sustained low DO2 leads to organ failure and death [1]. Low cardiac output states (cardiogenic, hypovolaemic and obstructive types of shock) and anaemic and hypoxic hypoxaemia are characterized by decreased DO2 but preserved oxygen extraction ratio. In distributive shock, the oxygen extraction capability is altered so that the critical oxygen extraction ratio is typically decreased [2]. Mixed venous oxygen saturation (SvO2), measured from the pulmonary artery, is used in the calculation of oxygen consumption and has been advocated as an indirect index of tissue oxygenation and a prognostic predictor in critically ill patients [36]. However, catheterization of the pulmonary artery is costly, has inherent risks and its usefulness remains subject to debate [79].

Near infrared spectroscopy (NIRS) is a technique that permits continuous, noninvasive, bedside monitoring of tissue oxygen saturation (Sto2) [9, 10]. We previously showed that thenar muscle StO2 during stagnant ischaemia decreases at a slower rate in patients with septic shock than in patients with severe sepsis or localized infection and in healthy volunteers [11]. Patients included in the study had normal heart function and were haemodynamically stable; they also had normal or higher StO2. However, in every day clinical practice, we noticed extreme low levels of StO2, especially in patients with cardiogenic shock.

Our aim in the present study was to evaluate skeletal muscle oxygenation in severe left heart failure with or without additional severe sepsis/septic shock and to compare with with SvO2. The hypothesis was that StO2 may estimate SvO2 in patients severe left heart failure and preserved oxygen extraction capability (without severe sepsis/septic shock), because blood flowing through upper limb muscles could importantly contribute to flow through the superior vena cava. On the other hand, in patients with decreased oxygen extraction capability (with severe sepsis/septic shock), we expected disagreement between StO2 and SvO2, because in these patients greater oxygen extraction can probably take place in organs other than skeletal muscles.

Materials and methods

Patients

The study protocol was approved by the National Ethics Committee of Slovenia; informed consent was obtained from all patients or their relatives. The study was performed during the period between October 2004 and June 2006. Following initial heamodynamic resuscitation, heart examination was performed in all patients admitted to our intensive care unit (ICU) using transthoracic ultrasound (Hewlett-Packard HD 5000; Hewlett-Packard, Andover, MA, USA). In patients with primary heart disease, low cardiac output and no signs of hypovolaemia, right heart catheterization with a pulmonary artery floating catheter (Swan-Ganz CCOmboV CCO/SvO2/CEDV; Edwards Lifesciences, Irvine, CA, USA) was performed at the descretion of the treating physician. The site of insertion was confirmed by the transducer waveform, the length of catheter insertion and chest radiography. Systemic arterial pressure was measured invasively using radial or femoral arterial catheterization.

Patients with severe left heart failure due to primary heart disease (left ventricular systolic ejection fraction < 40%, pulmonary artery occlusion pressure > 18 mmHg) were included. The patients were prospectively divided into two groups; group A included patients without severe sepsis or septic shock and group B included patients with additional severe sepsis or septic shock. Severe sepsis and septic shock were defined according to the 1992 American College of Chest Physicians and the Society of Critical Care Medicine consensus conference definitions [12].

All patients received standard treatment for localized infection, severe sepsis and septic or cardiogenic shock, including source control, fluid infusion, catecholamine infusion, replacement and/or support therapy for organ failure, intensive control of blood glucose and corticosteroid substitution therapy, in accordance to current Surviving Sepsis Campaign Guidelines [13]. Mechanically ventilated patients were sedated with midazolam and/or propofol infusion, and no paralytic agents were used.

Fifteen healthy volunteers served as a control group.

Measurements

Skeletal muscle oxygenation

Thenar muscle StO2 was measured noninvasively by NIRS (InSpectra™; Hutchinson Technology Inc., Hutchinson, MN, USA). Maximal thenar muscle StO2 was determined by moving the probe over the thenar prominence. StO2 was continuously monitored and stored in a computer using InSpectra™ software. The average StO2 over 15 seconds was used. Measurements were performed immediately after right heart catheterization using pulmonary artery floating catheter insertion (during the first 24 hours after admission). The time between admission and measurement is reported. Measurements in spontaneously breathing patients and healthy volunteers were taken after 15 minutes of bed rest, avoiding any muscular contractions.

Severity of disease

Sepsis-related Organ Failure Assessment (SOFA) score was calculated at the time of each measurement to assess the level of organ dysfunction [14]. Dobutamine, norepinephrine requirement represented the dose of drug during the StO2 measurement. Also reported is use of intra-aortic balloon pump during ICU stay.

Plasma lactate concentration was measured using enzymatic colorimetric method (Roche Diagnostics GmbH, Mannheim, Germany) at the time of each StO2 measurement.

Laboratory analysis

Blood was drawn from the pulmonary artery at the time of each StO2 measurement in order to determine the SvO2 (%). In view of the known problems that may arise during sampling from the pulmonary artery, including the possibility arterial blood may be contaminated with pulmonary capillary blood, all samples from this site were drawn over 30 seconds, using a low-negative pressure technique, and never with the balloon inflated. A standard volume of 1 ml blood was obtained from each side after withdrawal of dead-space blood and flushing fluid. All measurements were made using a cooximeter (RapidLab 1265; Bayer HealthCare AG, Leverkusen, Germany).

Study of agreement between trends of StO2 and SvO2

In ten patients from group A and eight patients from group B, StO2 and SvO2 (Vigilance CEDV; Edwards Lifesciences) were continuously monitored and recorded every 15 minutes for one hour to study agreement between trends in measured variables.

Data analysis

Data are expressed as mean ± standard deviation. Student's t-test, Kolmogorov-Smirnov Z test and χ2 test (Yates correction) were applied to analyze data (SPSS 10.0 for Windows™; SPSS Inc., Cary, NC, USA). One-way analysis of variance with Dunnett T3 test for post-hoc multiple comparisons were used to compare muscle tissue StO2 between healthy volunteers and both groups. Spearman correlation test was applied to determine correlation. To compare muscle tissue StO2 and SvO2, bias, systemic disagreement between measurements (mean difference between two measurements) and precision (the random error in measuring [standard deviation of bias]) were calculated [14]. The 95% limits of agreement were arbitrarily set, in accordance with Bland and Altman [15], as the bias ± 2 standard deviations. P < 0.05 (two-tailed) was considered statistically significant.

Results

Included in the study were 65 patients (36 women and 29 men; mean age 68 ± 14 years) with primary heart disease (ischaemic heart disease in 51 patients, aortic valve stenosis in 12 and dilated cardiomyopathy in two). In 24 patients (group A) severe left heart failure or cardiogenic shock but no additional severe sepsis/septic shock was the reason for ICU admission. In 25 patients severe sepsis and in 16 patients septic shock was diagnosed (group B; n = 41). Suspected pneumonia was main source of infection (35 patients [85%]), followed by urinary tract infection (six patients [15%]). In 80% of patients pathogenic bacteria were isolated.

There was no difference in age, sex, aetiology of primary heart disease, echocardiography data, time between admission and measurements, SOFA score, duration of ICU stay and survival between groups (Table 1). Fifteen healthy volunteers (eight women and seven men; age 40 ± 12 years) were included in the control group.
Table 1

Description of patients

Parameter

All (n = 65)

Group A (n = 24)

Group B (n = 41)

P value

Age (years)

69 ± 15

68 ± 14

70 ± 16

0.2

Female (n)

36

12

24

0.9

Ischaemic heart disease (n)

51

19

32

0.9

Aoritc stenosis (n)

12

4

8

0.9

Dilated cardiomyopathy (n)

2

1

1

0.7

LVEF (%)

30 ± 10

28 ± 12

32 ± 8

0.2

LVEDD (cm)

5.8 ± 0.9

5.9 ± 1.0

5.8 ± 0.8

0.3

Severe mitral regurgitation (n)

21

8

13

0.9

Time between admission and measurement (hours)

6.4 ± 4.4

6.0 ± 4.8

6.6 ± 4.5

0.6

SOFA score

11.8 ± 2.5

11.6 ± 2.5

11.9 ± 2.7

0.8

ICU stay (days)

8 ± 3

7 ± 4

10 ± 3

0.9

ICU survival (%

47

45

50

0.8

Group A includes patients with severe left heart failure without additional severe sepsis/septic shock, and group B includes patients with severe left heart failure with additional severe sepsis/septic shock. ICU, intensive care unit; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; SOFA, Sequential Organ Failure Assessment.

Patients in group A received higher doses of dobutamine (Table 2). There was no difference in lactate value, haemoglobin level and leucocyte count; however C-reactive protein and procalcitonin values were higher in group B patients (Table 3). Patients in group A had lower cardiac index, DO2 and SvO2, and higher oxygen extraction ratio compared with patients in group B (Table 4).
Table 2

Treatment of patients

Treatment

All (n = 65)

Group A (n = 24)

Group B (n = 41)

P value

Norepinephrine (mg/min)

0.048 ± 0.049

0.039 ± 0.042

0.051 ± 0.052

0.39

Dobutamine (mg/min)

0.40 ± 0.31

0.53 ± 0.33

0.33 ± 0.28

0.05

IABP (n)

15

15

0

0.01

Mechanical ventilation (n)

60

22

38

0.9

FiO2 (%)

72 ± 22

82 ± 19

68 ± 23

0.04

Group A includes patients with severe left heart failure without additional severe sepsis/septic shock, and group B includes patients with severe left heart failure with additional severe sepsis/septic shock. FiO2, fractional inspired oxygen; IABP, intra-aortic balloon pump.

Table 3

Laboratory data

Parameter

All (n = 65)

Group A (n = 24)

Group B (n = 41)

P value

Temperature (°C)

37.9 ± 0.9

38.0 ± 0.9

37.9 ± 0.9

0.9

Lactate (mmol/l)

3.5 ± 2.3

4.1 ± 2.5

3.1 ± 2.1

0.1

CRP (mg/l)

110 ± 84

78 ± 72

128 ± 86

0.02

PCT (mg/l)

5.0 ± 6.0

2.5 ± 2.7

6.5 ± 6.8

0.02

Leucocyte (× 106/l)

14.1 ± 7.2

14.5 ± 9.0

13.9 ± 5.2

0.6

Haemoglobin (mg/l)

112 ± 14

109 ± 11

114 ± 15

0.1

Creatinine (μmol/l)

199 ± 165

156 ± 148

227 ± 186

0.1

Arterial blood gas analysis

    

   pH

7.37 ± 0.03

7.38 ± 0.07

7.36 ± 0.1

0.5

   PCO2 (kPa)

4.8 ± 1.0

4.7 ± 1.1

4.9 ± 1.0

0.4

   PO2 (kPa)

16.6 ± 8.0

17.8 ± 10.8

15.9 ± 6.2

0.4

   HCO3 (mmol/l)

19.8 ± 5.7

17.1 ± 2.6

21.0 ± 6.9

0.01

   BE (mEq/l)

-4.8 ± 5.7

-7.4 ± 3.5

-3.6 ± 6.4

0.03

   SatHbO2 (%)

97 ± 2

97 ± 1

97 ± 3

0.3

Group A includes patients with severe left heart failure without additional severe sepsis/septic shock, and group B includes patients with severe left heart failure with additional severe sepsis/septic shock. BE, base excess; CRP, C-reactive protein; PCO2, partial carbon dioxide tension; PCO2, partial oxygen tension; PCT, procalcitonin; SatHbO2, haemoglobin oxygen saturation.

Table 4

Systemic haemodynamics and systemic oxygen transport data

Parameter

All (n = 65)

Group A (n = 24)

Group B (n = 41)

P value

Heart rate (beats/min)

111 ± 21

111 ± 24

111 ± 19

0.9

SAP (mmHg)

120 ± 22

122 ± 25

119 ± 22

0.8

DAP (mmHg)

73 ± 21

71 ± 22

74 ± 22

0.7

PAPs (mmHg)

56 ± 14

57 ± 13

56 ± 12

0.2

PAPd (mmHg)

28 ± 8

31 ± 8

27 ± 8

0.01

CVP (mmHg)

15 ± 4

17 ± 3

14 ± 5

0.051

PAOP (mmHg)

23 ± 6

24 ± 5

22 ± 7

0.9

CI (l/min per m2)

2.4 ± 0.7

2.1 ± 0.6

2.6 ± 0.7

0.01

SvO2 (%)

63 ± 12

56 ± 11

68 ± 10

0.01

DO2 (ml/min per m2)

366 ± 134

301 ± 90

404 ± 142

0.001

VO2 (ml/min per m2)

120 ± 42

125 ± 42

117 ± 41

0.3

O2ER (%)

35 ± 12

43 ± 12

31 ± 11

0.001

Group A includes patients with severe left heart failure without additional severe sepsis/septic shock, and group B includes patients with severe left heart failure with additional severe sepsis/septic shock. CI, cardiac index; CVP, central venous pressure; DAP, systemic diastolic artieral pressure; DO2, oxygen delivery; O2ER, oxygen extraction ratio; PAOP, pulmonary artery occlusion pressure; PAPd, pulmonary artery diastolic pressure; PAPs, pulmonary artery systolic pressure; SAP, systemic systolic arterial pressure; ScvO2, central venous oxygen saturation; SvO2, mixed venous oxygen saturation; VO2, oxygen consumption.

In group A StO2 was lower than in group B patients and in healthy volunteers (58 ± 13%, 90 ± 7% and 84 ± 4%, respectively; P < 0.001). StO2 was higher in group B patients than in healthy volunteers (P = 0.02). In group A StO2 correlated with SvO2 (r = 0.689, P = 0.002), but no correlation was observed between StO2 and SvO2 in group B (r = -0.091, P = 0.60; Figure 1). In group A StO2 slightly overestimated SvO2 (bias -2.3%, precision 4.6%; Figure 2). In group B StO2 overestimated SvO2, but important disagreement between these variables was observed. In three of our patients with septic shock a skeletal muscle StO2 of 75% or lower (lower bound of the 95% confidence interval for mean StO2 in control individuals) was detected.
Figure 1

Correlation between skeletal muscle StO2 and SvO2. Group A includes patients with severe left heart failure without severe sepsis/septic shock, and group B includes patients with primary heart disease and additional severe sepsis/septic shock. A statistically significant correlation was found in group A (r = 0.689, P = 0.002) but not in group B (r = -0.091, P = 0.60). StO2, tissue oxygenation; SvO2, mixed venous oxygen saturation.

Figure 2

Agreement between SvO2 and thenar muscle StO2 in the absence of severe sepsis/septic shock. Shown are Bland and Altman plots of agreement between SvO2 and thenar muscle StO2 in patients with left heart failure without severe sepsis/septic shock (n = 24), The unbroken line indicates the mean difference (bias), and broken lines indicate 95% limits of agreement (mean ± standard deviation). StO2, tissue oxygenation; SvO2, mixed venous oxygen saturation.

In 10 patients from group A 42 pairs of SvO2-StO2 changes were recorded. Changes in StO2 correlated with changes in SvO2 (r = 0.836, R2 = 0.776, P < 0.001); the equation for the regression line was as follows (Figure 3): ΔSvO2 (%) = 0.84 × ΔStO2 (%) - 0.67. In eight patients from group B 38 pairs of SvO2-StO2 changes were recorded. In group B changes in StO2 did not correlate with changes in SvO2 (r = 0.296, R2 = 0.098, P = 0.071).
Figure 3

Concordance between changes in SvO2 and changes in thenar muscle StO2 in the absence of severe sepsis/septic shock. Shown are changes in SvO2 and thenar muscle StO2 in 10 patients with severe left heart failure without additional severe sepsis/septic shock (group A; n = 40, r = 0.836, R2 = 0.776, P < 0.001; equation of the regression line: ΔSvO2 [%] = 0.84 × ΔStO2 [%] - 0.67). StO2, tissue oxygenation; SvO2, mixed venous oxygen saturation.

Plasma lactate concentrations correlated negatively with StO2 values in group A (n = 24; r = -0.522, P = 0.009, R2 = 0.263; lactate [mmol/l] = -0.104 × StO2 [%] + 10.25); there was no correlation between lactate and StO2 in group B.

Discussion

The main result of the study is that skeletal muscle StO2 does not estimate SvO2 in patients with severe left heart failure and additional severe sepsis or septic shock. However, in patients with severe left heart failure without additional severe sepsis or septic shock, the StO2 value could be used as a fast and noninvasive estimate of SvO2; also, the trend in StO2 may be considered a surrogate for the trend in SvO2.

Skeletal muscle StO2 in patients with severe heart failure and additional severe sepsis or septic shock

We previously detected high StO2 and slow deceleration in StO2 during stagnant ischaemia in septic patients [11]. Our data were in concordance with a previous report from De Blasi and coworkers [16]. Studies in animals and patients with sepsis confirmed the presence of increased tissue oxygen tension [17]. However, tissue oxygen consumption slows down in sepsis, and this correlates with the severity of sepsis [18]. Reduced cellular use/extraction of oxygen may be the problem rather than tissue hypoxia per se, because an increase in tissue oxygen tension is normally observed [19]. The high StO2 levels seen in our patients with additional severe sepsis or septic shock support this hypothesis. Mitochondrial dysfunction has been implicated by Ince and Sinaasappel [20]. This mitochondrial alteration was also shown to correlate with outcome in sepsis and septic shock [21].

The high StO2/low SvO2, seen in severe sepsis and septic shock, suggest blood flow redistribution. Thenar muscle StO2 probably correlates with central venous oxygen saturation (ScvO2), which is measured in a mixture of blood from head and both arms. In healthy resting individuals ScvO2 is slightly lower than SvO2 [22]. Blood in the inferior vena cava has high oxygen content because the kidneys do not utilize much oxygen but receive a high proportion of cardiac output [23]. As a result, inferior vena caval blood has higher oxygen content than blood from the upper body, and SvO2 is greater than ScvO2.

This relationship changes in the presence of cardiovascular instability. Scheinman and coworkers [24] performed the earliest comparison of ScvO2 and SvO2 in both haemodynamically stable and shocked patients. In stable patients ScvO2 was similar to SvO2. In patients with failing heart ScvO2 was slightly higher than SvO2 and in shock patients the difference between SvO2 and ScvO2 was even more pronounced (47.5 ± 15.11% and 58.0 ± 13.05%, respectively; P < 0.001). Lee and coworkers [25] described similar findings. Other, more detailed studies in mixed groups of critically ill patients designed to test whether the ScvO2 measurements could substitute for SvO2 demonstrated problematic large confidence limits [26] and poor correlation between the two values [27].

Most authors attribute this pattern to changes in the distribution of cardiac output that occur in the presence of haemodynamic instability. In shock states, blood flow to the splanchnic and renal circulations falls, whereas flow to the heart and brain is maintained [28]. This results in a fall in the oxygen content of blood in the inferior vena cava. As a consequence, in shock states the normal relationship is reversed and ScvO2 is greater than SvO2 [2325]. Consequently, when using ScvO2 (or probably StO2) as a treatment goal, the relative oxygen consumption of the superior vena cava system may remain stable at a time when oxidative metabolism of vital organs, such as the splanchnic region, may reach a level at which flow-limited oxygen consumption occurs, together with marked decrease in oxygen saturation. In this situation StO2 provides a falsely favourable impression of adequate body perfusion, because of the inability to detect organ ischemia in the lower part of the body.

In the present study three patients with septic shock had skeletal muscle StO2 of 75% or less (under the lower bound of the 95% confidence interval for the mean StO2 in control individuals); they were all in septic shock (lactate value > 2.5 mmol/l) with low cardiac index (< 2.0 l/min per m2). These patients were probably in an early under-resuscitated phase of septic shock. Low numbers of septic patients with low StO2 values did not allow us to study the agreement between StO2 and SvO2 in such patients; however, there was a wide range in StO2 values with SvO2 below 65%. Additional research is necessary to study muscle skeletal StO2 in under-resuscitated septic patients.

Skeletal muscle StO2 in patients with severe heart failure without additional severe sepsis or septic shock

Our data are supported by previous work conducted by Boekstegers and coworkers [29], who measured the oxygen partial pressure distribution in biceps muscle. They found low peripheral oxygen availability in cardiogenic shock compared with sepsis. In cardiogenic shock skeletal muscle partial pressure of oxygen correlated with systemic DO2 (r = 0.59, P < 0.001) and systemic vascular resistance (r = 0.74, P < 0.001). No correlation was found between systemic oxygen transport variables and skeletal muscle partial oxygen pressure in septic patients. These measurements were taken in the most common cardiovascular state in sepsis; this is in contrast to hypodynamic shock, which is only present in the very final stages of sepsis or in patients without adequate volume replacement [30]. In a subsequent study, those authors showed that even in the final state of hypodynamic septic shock, leading to death, the mean muscle partial oxygen pressure did not decrease to under 4.0 kPa before circulatory standstill took place [31].

In a human validation study [32] a significant correlation between NIRS-measured StO2 and venous oxygen saturation (r = 0.92, P < 0.05) was observed; the venous effluent was obtained from a deep forearm vein that drained the exercising muscle. StO2 was minimally affected by skin blood flow. Changes in limb perfusion affect StO2; skeletal muscle StO2 decreases during norepinephrine and increases during nitroprusside infusion.

In shock with preserved or even increased oxygen extraction, such as haemorrhagic shock, StO2 (as measured by NIRS in skeletal muscle, stomach and liver) correlated with systemic DO2 in a pig model [33]. Changes in skeletal muscle oxygen partial pressure were confirmed during haemorrhagic shock and resuscitation [34]. Continuous monitoring of skeletal muscle StO2 is already used in trauma patients, in whom it identifies the severity of shock [35]. Basal skeletal muscle StO2 can track systemic DO2 during and after resuscitation of trauma patients [36].

StO2 overestimated SvO2 (bias -2.5%) in the present study. This may be due to the NIRS method, which does not discriminate between compartments. It provides a global assessment of oxygenation in all vascular compartments (arterial, venous and capillary) in sample volume of underlying tissue. This is major limitation of the present study. The noninvasive measurement of only venous oxygen saturation is complicated by the fact that isolation of the contribution of venous compartment to the noninvasive optical signal is not straightforward. New methods like near-infrared spiroximetry, which measures venous oxygen saturation in tissue from the near-infrared spectrum of the amplitude of respiration-induced absorption oscillations, may lead to the design of a noninvasive optical instrument that can provide simultaneous and real-time measurements of local arterial, tissue and venous oxygen saturation [37].

In low flow states, in which controversies regarding monitoring persist [38], it appears logical to make use of both macro- and microcirculatory parameters to guide resuscitation efforts [39]. A large prospective study is currently being performed to evaluate the utility of additional StO2 regional monitoring to guide tissue oxygenation, in addition to the early goal-directed therapy proposed by Rivers and coworkers [40].

Conclusion

In patients with severe left heart failure without additional severe sepsis or septic shock, SvO2 provides a noninvasive estimate of and tracks with StO2. It should be emphasized that in patients with severe heart failure and additional severe sepsis or septic shock, skeletal muscle StO2 provides a falsely favourable impression of body perfusion.

Key messages

  • Skeletal muscle StO2 does not estimate SvO2 in patients with severe left heart failure and additional severe sepsis or septic shock.

  • StO2 values could be used to provide rapid, noninvasive estimation of SvO2; furthermore, the trend in StO2 may be considered a surrogate for the trend in SvO2.

Abbreviations

DO2

oxygen distribution

ICU: 

intensive care unit

NIRS: 

near infrared spectroscopy

ScvO2

central venous oxygen saturation

SOFA: 

Sepsis-related Organ Failure Assessment

StO2

tissue oxygenation

(SvO2): 

mixed venous oxygen saturation.

Declarations

Acknowledgements

The study was partly supported by Grant for Ministry of science and technology, Slovenia. We thank Igor Strahovnik, medical student, for conducting part of the StO2 measurements and Timotej Jagric, PhD, from the Department for Quantitative Economic Analysis, Faculty of Economics and Business, University of Maribor, Slovenia for statistical advice.

Authors’ Affiliations

(1)
Clinical Department for Intensive Care Medicine, University Clinical Centre

References

  1. Vincent JL, De Backer D: Oxygen transport: the oxygen delivery controversy. Intensive Care Med 2004, 30: 1990-1996. 10.1007/s00134-004-2384-4View ArticlePubMedGoogle Scholar
  2. Lim N, Dubois MJ, De Backer D, Vincent JL: Do all nonsurvivors of cardiogenic shock die with low cardiac index? Chest 2003, 124: 1885-1891. 10.1378/chest.124.5.1885View ArticlePubMedGoogle Scholar
  3. Goldman RH, Klughaupt M, Metcalf T, Spivak AP, Harrison DC: Measurement of central venous oxygen saturation in patients with myocardial infarction. Circulation 1968, 38: 941-946.View ArticlePubMedGoogle Scholar
  4. Kasnitz P, Druger GL, Zorra F, Simmons DH: Mixed venous oxygen tension and hyperlactemia. Survival in severe cardiopulmonary disease. JAMA 1976, 236: 570-574. 10.1001/jama.236.6.570View ArticlePubMedGoogle Scholar
  5. Krafft P, Steltzer H, Hiesmayr M, Klimscha W, Hammerle AF: Mixed venous oxygen saturation in critically ill septic shock patients. The role of defined events. Chest 1993, 103: 900-906.View ArticlePubMedGoogle Scholar
  6. Edwards JD: Oxygen transport in cardiogenic and septic shock. Crit Care Med 1991, 19: 658-663.View ArticlePubMedGoogle Scholar
  7. Dalen JE, Bone RC: Is it time to pull the pulmonary artery catheter? JAMA 1996, 276: 916-918. 10.1001/jama.276.11.916View ArticlePubMedGoogle Scholar
  8. Reinhart K, Radermacher P, Sprung CL, Phelan D, Bakker J, Steltzer H: PA catheterisation – quo vadis? Do we have to change the current practice with this monitoring device. Intensive Care Med 1997, 23: 605-609. 10.1007/s001340050379View ArticlePubMedGoogle Scholar
  9. Boushel R, Piantadosi CA: Near-infrared spectroscopy for monitoring muscle oxygenation. Acta Physiol Scand 2000, 168: 615-622. 10.1046/j.1365-201x.2000.00713.xView ArticlePubMedGoogle Scholar
  10. Wahr JA, Tremper KK, Samra S, Delpy DT: Near-infrared spectroscopy: theory and applications. J Cardiothorac Vasc Anesth 1996, 10: 406-418. 10.1016/S1053-0770(96)80107-8View ArticlePubMedGoogle Scholar
  11. Pareznik R, Voga G, Knezevic R, Podbregar M: Changes of muscle tissue oxygenation during stagnant ishemia in septic patients. Intensive Care Med 2006, 32: 87-92. 10.1007/s00134-005-2841-8View ArticlePubMedGoogle Scholar
  12. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101: 1644-1655.View ArticlePubMedGoogle Scholar
  13. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al.: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004, 30: 536-555. 10.1007/s00134-004-2398-yView ArticlePubMedGoogle Scholar
  14. Vincent JL, Moreno R, Takala J, Willatts S, De Medonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996, 22: 707-710.View ArticlePubMedGoogle Scholar
  15. Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurements. Lancet 1986, 21: 307-310.View ArticleGoogle Scholar
  16. De Blasi RA, Palmisani S, Alampi D, Mercieri M, Romao R, Collini S, Pinto G: Microvascular dysfunction and skeletal muscle oxygenation assessed by phase-modulation near-infrared spectroscopy in patients with septic shock. Intensive Care Med 2005, 31: 1661-1668. 10.1007/s00134-005-2822-yView ArticlePubMedGoogle Scholar
  17. Sair M, Etherington PJ, Winlove P, Ewans TW: Tissue oxygenation and perfusion in patients with systemic sepsis. Crit Care Med 2001, 29: 1343-1349. 10.1097/00003246-200107000-00008View ArticlePubMedGoogle Scholar
  18. Kreymann G, Grosser S, Buggisch P, Gottschall C, Matthaei S, Greten H: Oxygen consumption and resting metabolic rate in sepsis, sepsis syndrome, and septic shock. Crit Care Med 1993, 21: 1012-1019. 10.1097/00003246-199307000-00015View ArticlePubMedGoogle Scholar
  19. Rosser DM, Stidwill RP, Jacobson D, Singer M: Oxygen tension in the bladder epithelium increased in both high and low output endotoxemic sepsis. J Appl Physiol 1995, 79: 1878-1882.PubMedGoogle Scholar
  20. Ince C, Sinaasappel M: Microcirculatory oxygenation and shunting in sepsis and shock. Crit Care Med 1999, 27: 1369-1377. 10.1097/00003246-199907000-00031View ArticlePubMedGoogle Scholar
  21. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, Davies NA, Cooper CE, Singer M: Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002, 360: 219-223. 10.1016/S0140-6736(02)09459-XView ArticlePubMedGoogle Scholar
  22. Barratt-Boyes BG, Wood EH: The oxygen saturation of blood in the venae cavae, right-heart chambers, and pulmonary vessels of healthy subjects. J Lab Clin Med 1957, 50: 93-106.PubMedGoogle Scholar
  23. Cargill W, Hickam J: The oxygen consumption of the normal and diseased human kidney. J Clin Invest 1949, 28: 526.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Scheinman MM, Brown MA, Rapaport E: Critical assessment of use of central venous oxygen saturation as a mirror of mixed venous oxygen in severely ill cardiac patients. Circulation 1969, 40: 165-172.View ArticlePubMedGoogle Scholar
  25. Lee J, Wright F, Barber R, Stanley L: Central venous oxygen saturation in shock: a study in man. Anesthesiology 1972, 36: 472-478. 10.1097/00000542-197205000-00012View ArticlePubMedGoogle Scholar
  26. Edwards JD, Mayall RM: Importance of the sampling site for measurement of mixed venous oxygen saturation in shock. Crit Care Med 1998, 26: 1356-1360. 10.1097/00003246-199808000-00020View ArticlePubMedGoogle Scholar
  27. Martin C, Auffray JP, Badetti C, Perrin G, Papazian L, Gouin F: Monitoring of central venous oxygen saturation versus mixed venous oxygen saturation in critically ill patients. Intensive Care Med 1992, 18: 101-104. 10.1007/BF01705041View ArticlePubMedGoogle Scholar
  28. Forsyth R, Hoffbrand B, Melmon K: Re-distribution of cardiac output during hemorrhage in the unanesthetized monkey. Circ Res 1970, 27: 311.View ArticlePubMedGoogle Scholar
  29. Boekstegers P, Weidenhoefer St, Pilz G, Werdan K: Peripheral oxygen availability within skeletal muscle in sepsis and septic shock: comparison to limited infection and cardiogenic shock. Infection 1991, 19: 317-323. 10.1007/BF01645355View ArticlePubMedGoogle Scholar
  30. Parker MM, Parrillo JE: Septic shock: hemodynamics and pathogenesis. JAMA 1983, 250: 3324-3327. 10.1001/jama.250.24.3324View ArticlePubMedGoogle Scholar
  31. Boekstegers P, Weidenhoefer , Kapsner T, Werdan K: Skeletal muscle partial pressure of oxygen in patients with sepsis. Crit Care Med 1994, 22: 640-650. 10.1097/00003246-199404000-00021View ArticlePubMedGoogle Scholar
  32. Mancini DM, Bolinger L, Li H, Kendrick K, Chance B, Wilson JR: Validation of near-infrared spectroscopy in humans. J Appl Physiol 1994, 77: 2740-2747.PubMedGoogle Scholar
  33. Taylor JH, Beilman GJ, Conroy MJ, Mulier KE, Dean Myers Gruessner A, Hammer BE: Tissue energetics as measured by nuclear magnetic resonance spectroscopy during hemorrhagic shock. Shock 2004, 21: 58-64. 10.1097/01.shk.0000101674.49265.93View ArticlePubMedGoogle Scholar
  34. Clavijo-Alvarez JA, Sims CA, Pinsky MR, Puyana JC: Monitoring skeletal muscle and subcutaneous tissue acid-base status and oxygenation during hemorrhagic shock and resuscitation. Shock 2005, 24: 270-275. 10.1097/01.shk.0000172364.89128.28View ArticlePubMedGoogle Scholar
  35. Crookes BA, Cohn SM, Bloch S, Amortegui J, Manning R, Li P, Proctor MS, Hallal AH, Blackbourne LH, Benjamin R, et al.: Can near-infrared spectroscopy identify the severity of shock in trauma patients? J Trauma 2005, 58: 806-816.View ArticlePubMedGoogle Scholar
  36. McKinley BA, Marvin RG, Cocanour CS, Moore FA: Tissue hemoglobin O 2 saturation during resuscitation of traumatic shock monitored using near infrared spectroscopy. J Trauma 2000, 48: 637-642.View ArticlePubMedGoogle Scholar
  37. Franceschini MA, Boas DA, Zourabian A, Diamond SG, Nadgir S, Lin DW, Moore JB, Fantini S: Near-infrared spiroxymetry: noninvasive measurements of venous saturation in piglets and human subjects. J Appl Physiol 2002, 92: 372-384.PubMed CentralPubMedGoogle Scholar
  38. Sakr Y, Vincent JL, Reinhart K, Payen D, Wiedermann CJ, Zandstra DF, Sprung CL: Use of the pulmonary artery catheter is not associated with worse outcome in the ICU. Chest 2005, 128: 2722-2731. 10.1378/chest.128.4.2722View ArticlePubMedGoogle Scholar
  39. Verdant C, De Backer D: How monitoring of the microcirculation may help us at the bedside? Curr Opin Crit Care 2005, 11: 240-244. 10.1097/01.ccx.0000158849.94225.11View ArticlePubMedGoogle Scholar
  40. Rivers EP, McIntyre L, Morro DC, Rivers KK: Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity. CMAJ 2005, 173: 1054-1065.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Podbregar and Možina; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Comments